COMPASS PATHWAYS PLC (CMPS) Stock News

NASDAQ:CMPS - US20451W1018 - ADR

4.42 USD

-0.39 (-8.11%)

Last: 8/29/2025, 8:13:53 PM

4.46 USD

+0.04 (+0.9%)

After Hours: 8/29/2025, 8:13:53 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CMPS Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Compass Pathfinder Limited

Compass Pathways to Participate in Four Investor Conferences in September

7 days ago - By: Yahoo Finance - Mentions: RY RY.CA ABBV

AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug

a month ago - By: Compass Pathfinder Limited

Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA

a month ago - By: The Motley Fool

Compass (CMPS) Q2 Loss Improves 27%

a month ago - By: Benzinga - Mentions: BSAC BGC RMNI MTZ ...

Earnings Scheduled For July 31, 2025

2 months ago - By: Benzinga

Why Is Compass Pathways Stock Trading Lower On Monday?

a month ago - By: Compass Pathfinder

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

a month ago - By: Compass Pathfinder Limited

Compass Pathways Appoints Justin Gover to Board of Directors

a month ago - By: Compass Pathfinder Limited

Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

a month ago - By: The Motley Fool - Mentions: VKTX

These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?

2 months ago - By: Yahoo Finance

Cathie Wood’s ARK Adds 125K COMPASS Pathways plc (CMPS) Shares

2 months ago - By: Compass Pathfinder Limited

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

2 months ago - By: FN Media Group LLC - Mentions: NYSE SAGE MNMD ATAI

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

2 months ago - By: Yahoo Finance - Mentions: BABA

This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip?

2 months ago - By: Bloomberg

Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial

2 months ago - By: Compass Pathfinder Limited

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

4 months ago - By: Zacks Investment Research

COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know

4 months ago - By: Compass Pathfinder Limited

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

4 months ago - By: Compass Pathfinder Limited

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

4 months ago - By: Compass Pathfinder Limited

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities